3-(1-methylpyrrolidin-3-yl)-1H-indole | 151272-93-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-(1-methylpyrrolidin-3-yl)-1H-indole
• 英文别名: Indole, 3-(1-methyl-3-pyrrolidinyl)-
• CAS: 151272-93-4
• 化学式: C₁₃H₁₆N₂
• 分子量: 200.283
• InChiKey: GIUCRWSFDBHBDT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  19
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-(1-methylpyrrolidin-3-yl)-1H-indole 在 四(三苯基膦)钯 、 potassium acetate 、 sodium hydride 作用下， 以 N,N-二甲基乙酰胺 、 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 生成 10-(1-methylpyrrolidin-3-yl)-5-thia-4b-aza-indeno-[2,1-a]indene-5,5-dioxide
  参考文献：
  名称：

  Synthesis and Structure Activity Relationship of Rigidized Indolyl Pyrrolidine Derivatives as 5-HT6 Receptor Ligands

  摘要：

  一系列新型刚性吲哚基吡咯烷衍生物通过限制色氨酸胺氮原子与a和b碳的结合而设计。所有合成的衍生物在体外结合测定中对5-HT6R表现出中等亲和力。本通讯的主题是选定化合物的合成、结构活性关系（SAR）、药代动力学特征以及体内疗效。

  DOI：

  10.14233/ajchem.2013.15443
• 作为产物：
  描述：

  3-吲哚基琥珀酸 在 lithium aluminium tetrahydride 作用下， 反应 5.0h， 生成 3-(1-methylpyrrolidin-3-yl)-1H-indole
  参考文献：
  名称：

  Synthesis and Structure Activity Relationship of Rigidized Indolyl Pyrrolidine Derivatives as 5-HT6 Receptor Ligands

  摘要：

  一系列新型刚性吲哚基吡咯烷衍生物通过限制色氨酸胺氮原子与a和b碳的结合而设计。所有合成的衍生物在体外结合测定中对5-HT6R表现出中等亲和力。本通讯的主题是选定化合物的合成、结构活性关系（SAR）、药代动力学特征以及体内疗效。

  DOI：

  10.14233/ajchem.2013.15443

文献信息

• [EN] RORγ MODULATORS<br/>[FR] MODULATEURS DE ROR&Ggr;
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2015035278A1

  公开（公告）日：2015-03-12

  Described are RORγ modulators of the formula (I), or pharmaceutically acceptable salts thereof, wherein all substituents are defined herein. The invention includes stereoisomeric forms of the compounds of formula I, including stereoisomerically-pure, scalemic and racemic form, as well as tautomers thereof. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders.

  描述了公式（I）的RORγ调节剂，或其药学上可接受的盐，其中所有取代基在此处定义。该发明包括公式I化合物的立体异构体形式，包括立体异构纯、立体混合和消旋形式，以及其互变异构体。还提供了包含相同化合物的药物组合物。这些化合物和组合物在调节细胞中的RORγ活性的方法以及治疗患有疾病或紊乱的受试者的方法中是有用的，其中受试者在调节RORγ活性方面会从中获益，例如自身免疫和/或炎症性疾病。
• [EN] 3-(PYROLIDIN-3-L) INDOLES AS 5-HT6 RECEPTOR MODULATORS<br/>[FR] 3-(PYRROLIDINE-3-L)INDOLES EN TANT QUE MODULATEURS DU RECEPTEUR 5-HT6
  申请人：SUVEN LIFE SCIENCES

  公开号：WO2005066157A1

  公开（公告）日：2005-07-21

  The present invention describes 3-(Heterocyclic)indoles with the Formula (I), its stereoisomers and salts, wherein the substituents such as R, R1, R2, R3, R4, R10, R11, R12, R13, and R14 are described in the specification. The invention also provides a method to prepare compound with formula (I), pharmaceutical composition containing such compounds and method to manufacture a medicament. These compounds are useful in the treatment of various CNS disorders, hematological disorders, eating disorders, diseases associated with pain, respiratory disease, genito-urological disorders, cardio vascular diseases and cancer.

  本发明描述了具有化学式(I)的3-(杂环)吲哚，其立体异构体和盐，其中取代基如R、R1、R2、R3、R4、R10、R11、R12、R13和R14在说明书中有所描述。该发明还提供了制备具有化学式(I)的化合物的方法，含有这些化合物的药物组合物以及制造药物的方法。这些化合物在治疗各种中枢神经系统疾病、血液学疾病、进食障碍、与疼痛相关的疾病、呼吸系统疾病、泌尿生殖系统疾病、心血管疾病和癌症方面具有用途。
• A Direct Synthesis of 3-(Pyrrolidin-3-yl)indoles for Use As Conformationally Restricted Analogs of Tryptamines
  作者：John E. Macor、David H. Blank、Kevin Ryan、Ronald J. Post

  DOI：10.1055/s-1997-1214

  日期：1997.4

  An efficient, two step synthesis of 3-(pyrrolidin-3-yl)indoles 4 is described. Indoles react with maleimides in refluxing acetic acid affording 3-(indol-3-yl)succinimides 6. Reaction times and yields depend on the substituents on the indole 5. Direct reduction of the succinimides 6 with LAH affords the desired conformationally restricted tryptamine derivatives 4.

  本文描述了一种 3-(吡咯烷-3-基)吲哚 4 的高效两步合成法。吲哚与马来酰亚胺在回流乙酸中反应，生成 3-(吲哚-3-基)琥珀酰亚胺 6。反应时间和产量取决于吲哚 5 上的取代基。用 LAH 直接还原琥珀酰亚胺 6，可得到所需的构象受限的色胺衍生物 4。
• Heterocyclylindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands
  申请人：American Home Products Corporation

  公开号：US20020198213A1

  公开（公告）日：2002-12-26

  The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor. 1

  本发明提供了I式化合物及其在治疗与5-HT6受体相关或受其影响的疾病中的应用。
• 5-arylindolederivatives and their use as serotonin(5-ht1)agonists
  申请人：PFIZER INC.

  公开号：EP1094064A1

  公开（公告）日：2001-04-25

  A compound of the formula wherein R1 is n is 0, 1, or 2; A, B, C, and D are each independently nitrogen or carbon; R2, R3, R4, and R5 are each independently hydrogen, C1 to C6 alkyl, aryl, C1 to C3 alkyl-aryl, halogen, cyano, nitro, -(CH2)mNR14R15, -(CH2)mOR9, -SR9, -SO2NR14R15, -(CH2)mNR14SO2R15, -(CH2)mNR14CO2R9, -(CH2)mNR14COR9, -(CH2)mNR14CONHR9, -CONR14R15, or -CO2R9; R2 and R3, R3 and R4, or R4 and R5 may be taken together to form a five- to seven-membered alkyl ring, a six-membered aryl ring, a five- to seven-membered heteroalkyl ring having 1 heteroatom of N, O, or S, or a five- to six-membered heteroaryl ring having 1 or 2 heteroatoms of N, O, or S; R6 is hydrogen, -OR10, or -NHCOR10; R7, R8, R14, and R15 are each independently hydrogen, C1 to C6 alkyl, -(CH2)xOR11, C1 to C3 alkyl-aryl, aryl; R7 and R8 or R14 and R15 may be taken together to form a three- to six-membered ring; R9 is hydrogen, C1 to C6 alkyl, C1 to C3 alkyl-aryl, or aryl; R10 is hydrogen, C1 to C6 alkyl, or C1 to C3 alkyl-aryl; R11 is hydrogen, C1 to C6 alkyl, or C1 to C3 alkyl-aryl; m is 0, 1, 2, or 3; x is 2 or 3; a broken line represents an optional double bond; and the above aryl groups and the aryl moieties of the above alkyl-aryl groups are independently phenyl or substituted phenyl, wherein said substituted phenyl may be substituted with one to three of C1 to C4 alkyl, halogen, hydroxy, cyano, carboxamido, nitro, or C1 to C4 alkoxy; or a pharmaceutically acceptable satt thereof.

  式中的化合物 其中 R1 是 n为0、1或2；A、B、C和D各自独立地为氮或碳；-(CH2)mOR9、-SR9、-SO2NR14R15、-(CH2)mNR14SO2R15、-(CH2)mNR14CO2R9、-(CH2)mNR14COR9、-(CH2)mNR14CONHR9、-CONR14R15 或 -CO2R9；R2 和 R3、R3 和 R4 或 R4 和 R5 可组合成五至七元烷基环、六元芳基环、具有 1 个 N、O 或 S 杂原子的五至七元杂烷基环或具有 1 或 2 个 N、O 或 S 杂原子的五至六元杂芳基环；R6是氢、-OR10或-NHCOR10； R7、R8、R14和R15各自独立地是氢、C1至C6烷基、-(CH2)xOR11、C1至C3烷基芳基、芳基；R7 和 R8 或 R14 和 R15 可结合在一起形成三至六元环；R9 是氢、C1 至 C6 烷基、C1 至 C3 烷基芳基或芳基；R10 是氢、C1 至 C6 烷基或 C1 至 C3 烷基芳基；R11 是氢、C1 至 C6 烷基或 C1 至 C3 烷基芳基；m 是 0、1、2 或 3；x 是 2 或 3；断线代表任选双键；上述芳基和上述烷基芳基的芳基独立地为苯基或取代苯基，其中所述取代苯基可被 C1 至 C4 烷基、卤素、羟基、氰基、羧酰胺基、硝基或 C1 至 C4 烷氧基中的一至三个取代；或其药学上可接受的酯。